Cargando…
Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis
Autores principales: | Fakhouri, Walid, Sapin, Christophe, Holzkaemper, Thorsten, de la Torre, Inmaculada |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107070/ https://www.ncbi.nlm.nih.gov/pubmed/33742363 http://dx.doi.org/10.1007/s12325-021-01641-w |
Ejemplares similares
-
Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis
por: Fautrel, Bruno, et al.
Publicado: (2018) -
Authors’ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Pope, Janet, et al.
Publicado: (2021) -
Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
por: Van De Laar, Celine J, et al.
Publicado: (2020) -
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023) -
A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
por: Fakhouri, Walid, et al.
Publicado: (2020)